Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Testosterone isocaproate is a **small-molecule androgen ester** of testosterone in which testosterone is esterified with isocaproic acid to prolong release after intramuscular administration. It functions as a **prodrug of testosterone** and exerts its pharmacologic effect after hydrolysis to testosterone, which **agonizes the androgen receptor** to restore androgen signaling. The agent has been used in **androgen replacement therapy**, particularly for **male hypogonadism**, and is best known as one component of the multi-ester testosterone product **Sustanon 250** originally developed by **Organon**. As a distinct substance, testosterone isocaproate is not itself a combination drug, but a specific testosterone ester formulation component intended to provide a sustained release profile relative to unesterified testosterone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on testosterone isocaproate.